These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 8452657)

  • 41. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry.
    Diphoorn J; Cazzaniga S; Gamba C; Schroeder J; Citterio A; Rivolta AL; Vighi GD; Naldi L;
    Pharmacoepidemiol Drug Saf; 2016 Feb; 25(2):196-203. PubMed ID: 26687641
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Low serum folate among persons taking Fansidar (pyrimethamine plus sulfadoxine) for prophylaxis of malaria.
    Stürchler D; Holzer B
    Acta Trop; 1980 Sep; 37(3):243-8. PubMed ID: 6106361
    [No Abstract]   [Full Text] [Related]  

  • 43. Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.
    Peters PJ; Thigpen MC; Parise ME; Newman RD
    Drug Saf; 2007; 30(6):481-501. PubMed ID: 17536875
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Severe skin reactions. Toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema exsudativum multiforme majus and generalized bullous fixed drug exanthema].
    Rzany B; Mockenhaupt M; Baur S; Stocker U; Schöpf E
    Hautarzt; 1993 Aug; 44(8):549-54; quiz 554-6. PubMed ID: 8376113
    [No Abstract]   [Full Text] [Related]  

  • 45. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of cutaneous drug eruptions in adult Nigerians with HIV/AIDS.
    Salami TA; Asalu AF; Samuel SO
    Niger Postgrad Med J; 2010 Jun; 17(2):160-3. PubMed ID: 20539333
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and tolerability of artesunate plus sulfadoxine-pyrimethamine and sulfadoxine-pyrimethamine alone for the treatment of uncomplicated Plasmodium falciparum malaria in Peru.
    Marquiño W; Ylquimiche L; Hermenegildo Y; Palacios AM; Falconí E; Cabezas C; Arróspide N; Gutierrez S; Ruebush TK
    Am J Trop Med Hyg; 2005 May; 72(5):568-72. PubMed ID: 15891131
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cutaneous drug reactions in patients admitted to the dermatology unit at the University Hospital of the West Indies, Kingston, Jamaica.
    East-Innis AD; Thompson DS
    West Indian Med J; 2009 Jun; 58(3):227-30. PubMed ID: 20043529
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A large population-based follow-up study of trimethoprim-sulfamethoxazole, trimethoprim, and cephalexin for uncommon serious drug toxicity.
    Jick H; Derby LE
    Pharmacotherapy; 1995; 15(4):428-32. PubMed ID: 7479194
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical pattern of cutaneous drug eruption among children and adolescents in north India.
    Sharma VK; Dhar S
    Pediatr Dermatol; 1995 Jun; 12(2):178-83. PubMed ID: 7659648
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Fansidar hypersensitivity pneumonitis.
    McCormack D; Morgan WK
    Br J Dis Chest; 1987 Apr; 81(2):194-6. PubMed ID: 3651313
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Serious side effects of sulfadoxine/pyrimethamine as antimalarials].
    Christensen PK; Loft S; Olsen VV
    Ugeskr Laeger; 1983 Jan; 145(4):245. PubMed ID: 6845486
    [No Abstract]   [Full Text] [Related]  

  • 53. Leads from the MMWR. Adverse reactions to Fansidar and updated recommendations for its use in the prevention of malaria.
    JAMA; 1985 Jan; 253(4):483. PubMed ID: 3881605
    [No Abstract]   [Full Text] [Related]  

  • 54. Treatment of toxic epidermal necrolysis and a review of six cases.
    Ward DJ; Krzeminska EC; Tanner NS
    Burns; 1990 Apr; 16(2):97-104. PubMed ID: 2140940
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Assessment and management of cutaneous reactions with amifostine administration: findings of the ethyol (amifostine) cutaneous treatment advisory panel (ECTAP).
    Boccia R; Anné PR; Bourhis J; Brizel D; Daly C; Holloway N; Hymes S; Koukourakis M; Kozloff M; Turner M; Wasserman T
    Int J Radiat Oncol Biol Phys; 2004 Sep; 60(1):302-9. PubMed ID: 15337569
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Fansidar prophylaxis, therapy, and immune responses in rodent malaria (Plasmodium berghei).
    Ferraroni JJ; Speer CA
    J Parasitol; 1982 Aug; 68(4):609-15. PubMed ID: 6750070
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Surveillance for adverse drug reactions to combination antimalarial therapy with sulfadoxine-pyrimethamine plus artesunate in Peru.
    Cairo J; Durand S; Marquiño W; Cabezas C; Lachira A; Quintana F; Vegas W; Ruebush TK; Utz G; Bacon DJ
    Am J Trop Med Hyg; 2008 Jul; 79(1):42-4. PubMed ID: 18606762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Adverse reactions associated with pyrimethamine-sulfadoxine prophylaxis for Pneumocystis carinii infections in AIDS.
    Navin TR; Miller KD; Satriale RF; Lobel HO
    Lancet; 1985 Jun; 1(8441):1332. PubMed ID: 2860516
    [No Abstract]   [Full Text] [Related]  

  • 59. Fansidar-resistant Plasmodium falciparum infection from Tanzania.
    Vleugels MP; Wetsteyn JC; Meuwissen JH
    Trop Geogr Med; 1982; 34(3):263-5. PubMed ID: 6758246
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Open randomized study of artesunate-amodiaquine vs. chloroquine-pyrimethamine-sulfadoxine for the treatment of uncomplicated Plasmodium falciparum malaria in Nigerian children.
    Sowunmi A; Fehintola FA; Adedeji AA; Gbotosho GO; Tambo E; Fateye BA; Happi TC; Oduola AM
    Trop Med Int Health; 2005 Nov; 10(11):1161-70. PubMed ID: 16262741
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.